Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Sethera Therapeutics Appoints Biotech Pioneer Dr. Robert Langer to Head and Chair the Scientific Advisory Board and Brigadier General Larry Lunt to Board of Directors

By: Newsfile

Salt Lake City, Utah--(Newsfile Corp. - February 5, 2025) - Sethera Therapeutics announced the appointment of Dr. Robert Langer, a world-renowned scientist, entrepreneur, and co-founder of Moderna, to Head and Chair its Scientific Advisory Board. The company also welcomed Brigadier General Larry V. Lunt, USAF (Ret.), a distinguished leader with decades of strategic expertise, to its Board of Directors.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Scientific Leadership: Dr. Langer's expertise in drug delivery systems and tissue engineering will be invaluable in guiding Sethera's scientific strategy and advancing its pipeline of innovative peptide-based therapeutics.
  • Strategic Leadership: Brig. Gen. Lunt's strategic vision and proven ability to lead organizations through complex challenges will be essential as Sethera continues to grow and evolve.
  • Company's Position Strengthened: The addition of Dr. Langer and Brig. Gen. Lunt to Sethera's leadership team strengthens the company's position in the field of peptide therapeutics. With a focus on accessing complex molecular architectures, Sethera is developing therapies for a wide range of diseases and is poised to make significant contributions to the advancement of human health.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7294/239712_figure1.png

Click image above to view full announcement.


About Sethera Therapeutics

Sethera Therapeutics is a privately held biopharmaceutical company dedicated to transforming the field of peptide therapeutics. The company's proprietary platform technology enables the development of enzymatically-altered peptide-based therapies with enhanced efficacy, safety, and delivery. The Sethera platform potentially targets a wide range of therapeutic areas. Sethera is building a world-class team and is committed to advancing the field of peptide therapeutics and improving the lives of patients worldwide.

Contacts:

Chelli Miller
219-921-6823
chelli@contentcarnivores.com

Source: Sethera Therapeutics

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239712

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.